Loading…
Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis
Excess amount of cytokine produced by inflammatory stimuli contributes to the progression of myocardial damage in myocarditis. Some angiotensin II receptor type 1 antagonists are reported to inhibit proinflammatory cytokine production in vitro and in vivo. We tested the hypothesis that olmesartan, a...
Saved in:
| Published in: | Molecular and cellular biochemistry 2004-04, Vol.259 (1-2), p.217-222 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 222 |
| container_issue | 1-2 |
| container_start_page | 217 |
| container_title | Molecular and cellular biochemistry |
| container_volume | 259 |
| creator | Nimata, Masaomi Kishimoto, Chiharu Yuan, Zuyi Shioji, Keisuke |
| description | Excess amount of cytokine produced by inflammatory stimuli contributes to the progression of myocardial damage in myocarditis. Some angiotensin II receptor type 1 antagonists are reported to inhibit proinflammatory cytokine production in vitro and in vivo. We tested the hypothesis that olmesartan, a novel angiotensin II receptor type 1 antagonist, ameliorated experimental autoimmune myocarditis (EAM) in rats attributing to the suppression of inflammatory cytokines in the heart. We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The results showed that olmesartan decreased blood pressure significantly compared with the untreated group, but markedly reduced the severity of myocarditis by comparing the heart weight/body weight ratio, pericardial effusion scores, macroscopic scores and microscopic scores. Myocardial interleukin (IL)- 1beta expression by western blotting and IL-1beta-positive staining cells by immunohistochemistry were significantly lower in rats with EAM given olmesartan treatment compared with those of rats given vehicle. We conclude that Olmesartan ameliorates acute EAM in rats. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications. |
| doi_str_mv | 10.1023/B:MCBI.0000021379.82282.53 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1464505927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1464505927</sourcerecordid><originalsourceid>FETCH-LOGICAL-p267t-6f0c4762e7b4e527e81f8ad83b96c0347a618a0a7052763dd7b90d3e682f3cd63</originalsourceid><addsrcrecordid>eNpdkF1LwzAYhYMobk7_goRdebHWfLRJ6p0bfgwm3uh1ydK3I6NNapMO9u-tOG98OfBenIfD4SA0pySlhPH75cPbarlOyc8xymWRKsYUS3N-hqY0lzzJClqcoynhhCSKSjlBVyHsCaGj6CWa0JyyrGByig5LcFBbY3WDoa7BxIB9jX3TQtB91G6BNXb-AA3Wbmd9BBesw-s17sFAF32P47EDTEc76p13NsQFHjrvsDZDBKyH6G3bDg5we_RG95WNNlyji1o3AW5Of4Y-n58-Vq_J5v1lvXrcJB0TMiaiJiaTgoHcZpAzCYrWSleKbwthCM-kFlRpoiUZTcGrSm4LUnEQitXcVILP0N1vbtf7rwFCLFsbDDSNduCHUNJMZDnJxylGdP4P3fuhd2O7UuaCUZqpfIRuT9CwbaEqu962uj-Wf4Pyb2McekI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>756211485</pqid></control><display><type>article</type><title>Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis</title><source>Springer Nature</source><creator>Nimata, Masaomi ; Kishimoto, Chiharu ; Yuan, Zuyi ; Shioji, Keisuke</creator><creatorcontrib>Nimata, Masaomi ; Kishimoto, Chiharu ; Yuan, Zuyi ; Shioji, Keisuke</creatorcontrib><description>Excess amount of cytokine produced by inflammatory stimuli contributes to the progression of myocardial damage in myocarditis. Some angiotensin II receptor type 1 antagonists are reported to inhibit proinflammatory cytokine production in vitro and in vivo. We tested the hypothesis that olmesartan, a novel angiotensin II receptor type 1 antagonist, ameliorated experimental autoimmune myocarditis (EAM) in rats attributing to the suppression of inflammatory cytokines in the heart. We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The results showed that olmesartan decreased blood pressure significantly compared with the untreated group, but markedly reduced the severity of myocarditis by comparing the heart weight/body weight ratio, pericardial effusion scores, macroscopic scores and microscopic scores. Myocardial interleukin (IL)- 1beta expression by western blotting and IL-1beta-positive staining cells by immunohistochemistry were significantly lower in rats with EAM given olmesartan treatment compared with those of rats given vehicle. We conclude that Olmesartan ameliorates acute EAM in rats. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.</description><identifier>ISSN: 0300-8177</identifier><identifier>EISSN: 1573-4919</identifier><identifier>DOI: 10.1023/B:MCBI.0000021379.82282.53</identifier><identifier>PMID: 15124927</identifier><language>eng</language><publisher>Netherlands: Springer Nature B.V</publisher><subject>Administration, Oral ; Angiotensin II receptors ; Angiotensin II Type 1 Receptor Blockers - administration & dosage ; Animals ; Antihypertensive Agents - administration & dosage ; Autoimmune Diseases - chemically induced ; Autoimmune Diseases - immunology ; Blood pressure ; Body weight ; Cytokines ; Dose-Response Relationship, Drug ; Female ; Imidazoles - administration & dosage ; Interleukin-1 - biosynthesis ; Male ; Myocarditis - chemically induced ; Myocarditis - drug therapy ; Myocarditis - immunology ; Myocarditis - metabolism ; Myocarditis - pathology ; Myocardium - metabolism ; Myocardium - pathology ; Myosins - administration & dosage ; Myosins - immunology ; Olmesartan Medoxomil ; Rats ; Rats, Inbred Lew ; Receptor, Angiotensin, Type 1 - immunology ; Rodents ; Swine ; Tetrazoles - administration & dosage</subject><ispartof>Molecular and cellular biochemistry, 2004-04, Vol.259 (1-2), p.217-222</ispartof><rights>Kluwer Academic Publishers 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15124927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nimata, Masaomi</creatorcontrib><creatorcontrib>Kishimoto, Chiharu</creatorcontrib><creatorcontrib>Yuan, Zuyi</creatorcontrib><creatorcontrib>Shioji, Keisuke</creatorcontrib><title>Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis</title><title>Molecular and cellular biochemistry</title><addtitle>Mol Cell Biochem</addtitle><description>Excess amount of cytokine produced by inflammatory stimuli contributes to the progression of myocardial damage in myocarditis. Some angiotensin II receptor type 1 antagonists are reported to inhibit proinflammatory cytokine production in vitro and in vivo. We tested the hypothesis that olmesartan, a novel angiotensin II receptor type 1 antagonist, ameliorated experimental autoimmune myocarditis (EAM) in rats attributing to the suppression of inflammatory cytokines in the heart. We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The results showed that olmesartan decreased blood pressure significantly compared with the untreated group, but markedly reduced the severity of myocarditis by comparing the heart weight/body weight ratio, pericardial effusion scores, macroscopic scores and microscopic scores. Myocardial interleukin (IL)- 1beta expression by western blotting and IL-1beta-positive staining cells by immunohistochemistry were significantly lower in rats with EAM given olmesartan treatment compared with those of rats given vehicle. We conclude that Olmesartan ameliorates acute EAM in rats. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.</description><subject>Administration, Oral</subject><subject>Angiotensin II receptors</subject><subject>Angiotensin II Type 1 Receptor Blockers - administration & dosage</subject><subject>Animals</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Autoimmune Diseases - chemically induced</subject><subject>Autoimmune Diseases - immunology</subject><subject>Blood pressure</subject><subject>Body weight</subject><subject>Cytokines</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Imidazoles - administration & dosage</subject><subject>Interleukin-1 - biosynthesis</subject><subject>Male</subject><subject>Myocarditis - chemically induced</subject><subject>Myocarditis - drug therapy</subject><subject>Myocarditis - immunology</subject><subject>Myocarditis - metabolism</subject><subject>Myocarditis - pathology</subject><subject>Myocardium - metabolism</subject><subject>Myocardium - pathology</subject><subject>Myosins - administration & dosage</subject><subject>Myosins - immunology</subject><subject>Olmesartan Medoxomil</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Receptor, Angiotensin, Type 1 - immunology</subject><subject>Rodents</subject><subject>Swine</subject><subject>Tetrazoles - administration & dosage</subject><issn>0300-8177</issn><issn>1573-4919</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdkF1LwzAYhYMobk7_goRdebHWfLRJ6p0bfgwm3uh1ydK3I6NNapMO9u-tOG98OfBenIfD4SA0pySlhPH75cPbarlOyc8xymWRKsYUS3N-hqY0lzzJClqcoynhhCSKSjlBVyHsCaGj6CWa0JyyrGByig5LcFBbY3WDoa7BxIB9jX3TQtB91G6BNXb-AA3Wbmd9BBesw-s17sFAF32P47EDTEc76p13NsQFHjrvsDZDBKyH6G3bDg5we_RG95WNNlyji1o3AW5Of4Y-n58-Vq_J5v1lvXrcJB0TMiaiJiaTgoHcZpAzCYrWSleKbwthCM-kFlRpoiUZTcGrSm4LUnEQitXcVILP0N1vbtf7rwFCLFsbDDSNduCHUNJMZDnJxylGdP4P3fuhd2O7UuaCUZqpfIRuT9CwbaEqu962uj-Wf4Pyb2McekI</recordid><startdate>200404</startdate><enddate>200404</enddate><creator>Nimata, Masaomi</creator><creator>Kishimoto, Chiharu</creator><creator>Yuan, Zuyi</creator><creator>Shioji, Keisuke</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope></search><sort><creationdate>200404</creationdate><title>Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis</title><author>Nimata, Masaomi ; Kishimoto, Chiharu ; Yuan, Zuyi ; Shioji, Keisuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p267t-6f0c4762e7b4e527e81f8ad83b96c0347a618a0a7052763dd7b90d3e682f3cd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Angiotensin II receptors</topic><topic>Angiotensin II Type 1 Receptor Blockers - administration & dosage</topic><topic>Animals</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Autoimmune Diseases - chemically induced</topic><topic>Autoimmune Diseases - immunology</topic><topic>Blood pressure</topic><topic>Body weight</topic><topic>Cytokines</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Imidazoles - administration & dosage</topic><topic>Interleukin-1 - biosynthesis</topic><topic>Male</topic><topic>Myocarditis - chemically induced</topic><topic>Myocarditis - drug therapy</topic><topic>Myocarditis - immunology</topic><topic>Myocarditis - metabolism</topic><topic>Myocarditis - pathology</topic><topic>Myocardium - metabolism</topic><topic>Myocardium - pathology</topic><topic>Myosins - administration & dosage</topic><topic>Myosins - immunology</topic><topic>Olmesartan Medoxomil</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Receptor, Angiotensin, Type 1 - immunology</topic><topic>Rodents</topic><topic>Swine</topic><topic>Tetrazoles - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nimata, Masaomi</creatorcontrib><creatorcontrib>Kishimoto, Chiharu</creatorcontrib><creatorcontrib>Yuan, Zuyi</creatorcontrib><creatorcontrib>Shioji, Keisuke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database (ProQuest)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><jtitle>Molecular and cellular biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nimata, Masaomi</au><au>Kishimoto, Chiharu</au><au>Yuan, Zuyi</au><au>Shioji, Keisuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis</atitle><jtitle>Molecular and cellular biochemistry</jtitle><addtitle>Mol Cell Biochem</addtitle><date>2004-04</date><risdate>2004</risdate><volume>259</volume><issue>1-2</issue><spage>217</spage><epage>222</epage><pages>217-222</pages><issn>0300-8177</issn><eissn>1573-4919</eissn><abstract>Excess amount of cytokine produced by inflammatory stimuli contributes to the progression of myocardial damage in myocarditis. Some angiotensin II receptor type 1 antagonists are reported to inhibit proinflammatory cytokine production in vitro and in vivo. We tested the hypothesis that olmesartan, a novel angiotensin II receptor type 1 antagonist, ameliorated experimental autoimmune myocarditis (EAM) in rats attributing to the suppression of inflammatory cytokines in the heart. We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The results showed that olmesartan decreased blood pressure significantly compared with the untreated group, but markedly reduced the severity of myocarditis by comparing the heart weight/body weight ratio, pericardial effusion scores, macroscopic scores and microscopic scores. Myocardial interleukin (IL)- 1beta expression by western blotting and IL-1beta-positive staining cells by immunohistochemistry were significantly lower in rats with EAM given olmesartan treatment compared with those of rats given vehicle. We conclude that Olmesartan ameliorates acute EAM in rats. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.</abstract><cop>Netherlands</cop><pub>Springer Nature B.V</pub><pmid>15124927</pmid><doi>10.1023/B:MCBI.0000021379.82282.53</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8177 |
| ispartof | Molecular and cellular biochemistry, 2004-04, Vol.259 (1-2), p.217-222 |
| issn | 0300-8177 1573-4919 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1464505927 |
| source | Springer Nature |
| subjects | Administration, Oral Angiotensin II receptors Angiotensin II Type 1 Receptor Blockers - administration & dosage Animals Antihypertensive Agents - administration & dosage Autoimmune Diseases - chemically induced Autoimmune Diseases - immunology Blood pressure Body weight Cytokines Dose-Response Relationship, Drug Female Imidazoles - administration & dosage Interleukin-1 - biosynthesis Male Myocarditis - chemically induced Myocarditis - drug therapy Myocarditis - immunology Myocarditis - metabolism Myocarditis - pathology Myocardium - metabolism Myocardium - pathology Myosins - administration & dosage Myosins - immunology Olmesartan Medoxomil Rats Rats, Inbred Lew Receptor, Angiotensin, Type 1 - immunology Rodents Swine Tetrazoles - administration & dosage |
| title | Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A53%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20effects%20of%20olmesartan,%20a%20novel%20angiotensin%20II%20receptor%20type%201%20antagonist,%20upon%20acute%20autoimmune%20myocarditis&rft.jtitle=Molecular%20and%20cellular%20biochemistry&rft.au=Nimata,%20Masaomi&rft.date=2004-04&rft.volume=259&rft.issue=1-2&rft.spage=217&rft.epage=222&rft.pages=217-222&rft.issn=0300-8177&rft.eissn=1573-4919&rft_id=info:doi/10.1023/B:MCBI.0000021379.82282.53&rft_dat=%3Cproquest_pubme%3E1464505927%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p267t-6f0c4762e7b4e527e81f8ad83b96c0347a618a0a7052763dd7b90d3e682f3cd63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=756211485&rft_id=info:pmid/15124927&rfr_iscdi=true |